Treatment of Drug-Susceptible Tuberculosis

Beth Shoshana Zha; Payam Nahid

doi:10.1016/j.ccm.2019.07.006

Treatment of Drug-Susceptible Tuberculosis

Clin Chest Med. 2019 Dec;40(4):763-774. doi: 10.1016/j.ccm.2019.07.006.

Authors

Beth Shoshana Zha¹, Payam Nahid²

Affiliations

¹ Department of Pulmonary, Critical Care, Allergy and Sleep Medicine, University of California, San Francisco, Box 0111, 513 Parnassus Avenue, San Francisco, CA 94117, USA.
² Department of Pulmonary, Critical Care, Allergy and Sleep Medicine, University of California, San Francisco, Box 0841 MD, 1001 Potrero Avenue, 5J6, San Francisco, CA 94110, USA. Electronic address: pnahid@ucsf.edu.

PMID: 31731983
DOI: 10.1016/j.ccm.2019.07.006

Abstract

Mycobacterium tuberculosis is a major public health concern and requires prompt treatment. Goals of treatment include curing the individual patient and protecting the community from ongoing tuberculosis transmission. To achieve durable cure, regimens must include multiple agents given concurrently and in a manner to ensure completion of therapy. This article focuses on preferred regimens of drug-susceptible tuberculosis under current guidelines by the American Thoracic Society, Centers for Disease Control and Prevention, and Infectious Diseases Society of America and World Health Organization. In addition, topics including patient centered care, poor treatment outcomes, and adverse effects are also discussed.

Keywords: Drug-susceptible Mycobacterium tuberculosis; HIV and Mycobacterium tuberculosis co-infection; M tuberculosis treatment supervision and patient-centered care; Mycobacterium tuberculosis treatment regimen.

Publication types

Review

MeSH terms

Antitubercular Agents / pharmacology
Antitubercular Agents / therapeutic use*
Humans
Treatment Outcome
Tuberculosis / therapy*

Substances

Antitubercular Agents